CSBR 241220 5.00P (CSBR241220P5000) Stock Options, News & Quotes

US OptionsDetailed Quotes

CSBR241220P5000

Watchlist

0.11
-0.19-63.33%

15min DelayClose Dec 13 16:00 ET

0.11High0.05Low

Intraday

5D
Daily

News

Further Upside For Champions Oncology, Inc. (NASDAQ:CSBR) Shares Could Introduce Price Risks After 38% Bounce
Simply Wall St49minutes ago
Craig-Hallum Maintains Buy on Champions Oncology, Raises Price Target to $8
BenzingaDec 12 11:23 ET · Ratings
Champions Oncology Analyst Ratings
BenzingaDec 12 11:22 ET · Ratings
Express News | Champions Oncology Inc : Craig-Hallum Raises Target Price to $8 From $6
ReutersDec 12 07:41 ET
Stocks to Watch: Adobe, Champions Oncology, DBV Technologies
WSJDec 11 18:40 ET
Champions Oncology, Inc. (CSBR) Q2 2025 Earnings Call Transcript
Earnings Call TranscriptsDec 11 18:02 ET

Comments

Stock_Drift

Dec 12 04:24

Pre Market Ticks. 5:23am 12/12

$Alset (AEI.US)$ $SRM Entertainment (SRM.US)$ $Champions Oncology (CSBR.US)$ $Safe & Green (SGBX.US)$ $JIADE (JDZG.US)$ $Charles & Colvard (CTHR.US)$ $Coeptis Therapeutics (COEP.US)$ $Nuburu (BURU.US)$ $DBV Technologies (DBVT.US)$ $Wheeler Real Estate Investment Trust Inc (WHLR.US)$ $AmpliTech Group (AMPG.US)$ $Palisade Bio (PALI.US)$
📊⚡️📊

Jaguar8

Dec 11 15:01

NEWS ER

$Champions Oncology (CSBR.US)$
Champions Oncology Reports Quarterly Revenue of $13.5 Million Adjusted EBITDA of $1.1 Million
Wednesday, 11th December at 4:00 pm
HACKENSACK, NJ / ACCESSWIRE / December 11, 2024 / Champions Oncology, Inc. (NASDAQ: CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its second quarter of fiscal 2025, ended October 31, 2024.
Second Quarter and Recent Highlights:...

jimmy the trader

Sep 11 16:09

Very nice 👍 late entry but still made good

$Champions Oncology (CSBR.US)$

Jaguar8

Sep 11 15:54

NEWS ER

$Champions Oncology (CSBR.US)$
Champions Oncology Reports Quarterly Revenue of $14.1 Million Adjusted EBITDA of $2.0 Million
Positive
▪️Revenue increased 12% year-over-year to $14.1 million
▪️Margin improved to 50% from 38.8% in the previous year
▪️Achieved adjusted EBITDA of $2.0 million, compared to a loss of $1.7 million last year
▪️Reported net income of $1.3 million
▪️Total costs and operating expenses decreased by $2.4 million or 15.8%
▪️Cost of oncology services decreased by 8.0%
▪️...

Trytosaveabit

Sep 11 15:15

$Champions Oncology (CSBR.US)$ First Quarter Highlights:
Total revenue increased 12% to $14.1 million
Margin improved to 50%
Adjusted EBITDA of $2.0 million
Net income of $1.3 million
EPS 0.01 a 94%+ increase